SUMMARY Twenty two patients with heart failure were studied in a double blind crossover trial to compare amiodarone (200 mg/day) with placebo. Each agent was given for three months. Extrasystoles and complex ventricular arrhythmias were common during ambulatory electrocardiographic monitoring and during exercise testing at entry to the study. Breathlessness and tiredness as assessed by visual analogue scores and duration of treadmill exercise did not become worse during amiodarone treatment. During the placebo and amiodarone phases of the study left ventricular ejection fraction and cardiac index determined by first pass radionuclide ventriculography were similar, both at rest and during upright bicycle exercise. Exercise induced ventricular tachycardia was abolished and simple and complex ventricular arrhythmias observed on 24 hour ambulatory monitoring were greatly diminished during amiodarone treatment. Three patients died, all suddenly, during the placebo phase. In two patients amiodarone was withdrawn after a further myocardial infarction in one and a worsening of symptoms of ventricular arrhythmia in the other.
SUMMARY Twenty two patients with heart failure were studied in a double blind crossover trial to compare amiodarone (200 mg/day) with placebo. Each agent was given for three months. Extrasystoles and complex ventricular arrhythmias were common during ambulatory electrocardiographic monitoring and during exercise testing at entry to the study. Breathlessness and tiredness as assessed by visual analogue scores and duration of treadmill exercise did not become worse during amiodarone treatment. During the placebo and amiodarone phases of the study left ventricular ejection fraction and cardiac index determined by first pass radionuclide ventriculography were similar, both at rest and during upright bicycle exercise. Exercise induced ventricular tachycardia was abolished and simple and complex ventricular arrhythmias observed on 24 hour ambulatory monitoring were greatly diminished during amiodarone treatment. Three patients died, all suddenly, during the placebo phase. In two patients amiodarone was withdrawn after a further myocardial infarction in one and a worsening of symptoms of ventricular arrhythmia in the other.
In contrast with other antiarrhythmic agents amiodarone is effective in suppressing ventricular arrhythmias in heart failure without causing adverse haemodynamic effects. Because frequent ventricular arrhythmias are known to be associated with a poor prognosis in heart failure, these data suggest that amiodarone may improve the poor prognosis in patients with heart failure.
Most patients with chronic heart failure primarily caused by left ventricular dysfunction die suddenly, not from progressively worsening heart failure and pulmonary oedema`3 but presumably from ventricular arrhythmias. Asymptomatic ventricular arrhythmias are often found on ambulatory electrocardiographic monitoring45 and several workers have noted an association between their occurrence and the poor prognosis of patients with heart failure. 2 46 Thus there may be a place for antiarrhythmic treatment in patients with heart failure and ventricular arrhythmias. The negative inotropic effects of many antiarrhythmic agents7 - Accepted for publication 24 November 1986 can reduce the frequency of arrhythmias in patients with heart failure.
Amiodarone, a class III antiarrhythmic agent, has a unique electrophysiological mode of action'2 and in addition is a powerful coronary and peripheral vasodilator. '3 14 Although amiodarone also has been found to have acute negative inotropic effects15 16 when given in large intravenous doses, which may be due to a non-competitive adrenergic antagonism, this is less apparent during long term use. 15 We know of no controlled studies on the long term effects of amiodarone in patients with heart failure. In the present study we have investigated the effects of medium term amiodarone treatment on symp-Treatment with amiodarone of patients in heart failure present for more than six months, into a double blind crossover study with treatment phases (amiodarone or placebo) lasting three months. Ten received amiodarone as the first treatment and 12 placebo. Both treatments were visually identical. The mean (SD) age of the patients was 56 (8) years, the median daily dose of frusemide was 120mg (range 40-200 mg), mean (SD) end diastolic left ventricular dimension 6 8 (0 9) cm (normal < 5-6 cm), and mean (SD) fractional shortening 14 3 (1 5) % (normal > 28%). All had stable heart failure; 10 were in New York Heart Association functional class III and 12 were in class II. Sixteen patients were taking digoxin (median daily dose 0 25 mg/day, range 0 0625-0 375), though all were in sinus rhythm. The diagnosis of congestive (dilated) cardiomyopathy in eight and ischaemic heart disease in 14 was established at cardiac catheterisation. Patients were selected because they had heart failure and not because they had serious symptomatic ventricular arrhythmias.
Ten patients were taking captopril, which had been started at least three months before entry to the study (mean 1 
BIOCHEMICAL ANALYSIS
Blood was taken at each visit for the measurement of serum urea, creatinine, digoxin, and electrolytes and also for plasma active renin concentration,17 angiotensin II,`aldosterone,9 catecholamines,20 and for thyroid function at baseline and at the end of each treatment phase. Plasma amiodarone concentrations were measured 24 hours after the last dose of the drug. Pulmonary function tests were performed at baseline and at the end of each treatment phase. In addition, patients were assessed clinically at one, two, four, and eight weeks after each change of treatment.
STATISTICAL ANALYSIS
Order and period effects were excluded by comparing the differences between observations for the amiodarone and placebo phases of the two groups by means of two-sample t tests; results for the amiodarone and placebo treatment phases were com- 24 hours. During exercise all but one of the patients in whom asymptomatic ventricular tachycardia developed were limited by breathlessness or fatigue. Five other patients had episodes of self terminating ventricular tachycardia during exercise testing.
The radionuclide ejection fraction was 20 (9) % at rest and rose to 25 (10) % (p < 0 05) on exercise. No patient was hypokalaemic on admission to the study (3 8 (03) (3 5-4 6) mmol/l (mean (SD) and range)).
REPRODUCIBILITY OF RADIONUCLIDE DATA
The reproducibility of left ventricular ejection fraction was tested by correlating baseline and placebo data; it was accurate for both rest and exercise studies (figs 3 and 4). Cardiac output during baseline and placebo periods was consistent at rest but less so during exercise (figs 3 and 4). This lack of consistency could not be entirely accounted for by biological variability because the peak exercise heart rates during the two tests were similar. DOUBLE BLIND STUDY Symptoms Table 1 shows that visual analogue scores for breathlessness and ankle swelling were unaffected by amiodarone, whereas tiredness showed a statistically insignificant tendency to increase.
Heart rate and blood pressure (table 1) Both supine and upright heart rate were significantly lower on amiodarone. After seven days of treatment these two variables were significantly lower on amiodarone than on placebo ( fig 5) . Systolic blood pressure, supine or erect, was unaltered by amiodarone treatment, though diastolic blood pressure in the supine position alone was lower during amiodarone treatment. No difference in the heart rate or blood pressure response to amiodarone was noted in patients treated with captopril.
group.bmj.com on April 18, 2017 -Published by http://heart.bmj.com/ Downloaded from Treatment with amiodarone of patients in heart failure Cleland, Dargie, Findlay, Wilson ing the placebo phase. Heart rate and blood pressure responses were similar during the placebo and amiodarone phases. Rest and exercise ejection fractions were not altered by amiodarone, nor was the increase in ejection fraction during exercise. We found no change in regional wall motion scores and no differences between patients with heart failure caused by ischaemic heart disease and those in whom it had another cause. These groups may have been too small to show any real difference, however.
Biochemistry (table 3) Concentrations of serum sodium, potassium, urea, and creatinine were unchanged. Plasma concentrations of renin, angiotensin II, aldosterone, and noradrenaline were also unchanged during amiodarone treatment. Serum digoxin rose significantly on amiodarone. Digoxin dosage had been reduced before the study to attain baseline concentrations at the lower end of the therapeutic range. A toxic concentration of serum digoxin was not found in any patient and the dose of digoxin was not altered during the study. During amiodarone treatment serum triiodothyronine concentrations fell while the concentration of serum thyroxine increased. Thyroid stimulating hormone concentrations also increased during amiodarone treatment. Plasma amiodarone concentrations were negligible during the placebo phase of the study.
lead electrocardiogram (fig 5)
Heart rate was reduced and QTc prolonged after one and twelve weeks' treatment with amiodarone ( fig 5) .
In most patients the PR interval did not increase. 88 (16) 93 (15) 94 (11) Total lung capacity (O°)
97 (17) 97 (15) 100 (15 Clinical outcome Three patients died during the placebo phase of the study. All died suddenly with no prior worsening of symptoms. All three had both ventricular tachycardia on exercise testing and on 48 hour ambulatory monitoring. All three were taking digoxin; however, serum concentrations at the last clinic visit had been normal. One patient had a myocardial infarction during the amiodarone phase from which he made an uneventful recovery; this patient was withdrawn from the study. In one patient arrhythmias became much worse after a week on amiodarone and this patient was also withdrawn from the study. Sub In a double blind study we have demonstrated that amiodarone in a relatively low dose of 200 mg/day can appreciably suppress ventricular arrhythmias, both during ambulatory monitoring and during treadmill exercise testing, without worsening symptoms in patients with heart failure of New York Heart Association grade II-III. Moreover, exercise performance and radionuclide ejection fraction both at rest and during exercise were maintained. The negative inotropic effects of amiodarone might have been offset not only by systemic vasodilatation but also by coronary vasodilatation. In the presence of clinically inapparent reversible myocardial ischaemia, which may occur in dilated cardiomyopathy as well as in heart failure caused by ischaemic heart disease, the improvement in the myocardial supply:demand ratio by amiodarone may have maintained cardiac output and ejection fraction.
Resting heart rate was reduced and QTc was prolonged after only one week of amiodarone treatment, which suggests an early onset of electrophysiological action; these effects persisted throughout the 12 week treatment period. The corrected QT interval is thought to correlate with plasma and myocardial concentrations of amiodarone30 31; however, the above effects occurred at relatively low concentrations of plasma amiodarone. In the eight patients for whom we have samples, plasma amiodarone concentrations were quite low on a maintenance dose of 200mg/day.32 There were several possible explanations for this. Firstly, patients may not have reached steady state concentrations because the half life for elimination of amiodarone is probably more than one month.32 Amiodarone has a rapid initial distribution phase,32 and as samples were taken 24 hours after the last dose of amiodarone the measured concentration could have been appreciably lower than the maximum.
The reduction in heart rate on amiodarone was accompanied by a small increase in stroke volume, 
EFFECTS OF TREATMENT
The effect of an antiarrhythmic agent on the prognosis in heart failure has been investigated in another controlled trial.11 In that study procainamide did not improve prognosis; however, the groups were not randomly allocated to treatment and the efficacy of arrhythmia suppression was not commented on. We are unaware of any previous study that has investigated concurrently the long term haemodynamic and electrophysiological effects of antiarrhythmic drugs in heart failure. Some antiarrhythmic drugs such as disopyramide and flecainide seem to be unsuitable for use in heart failure because of their negative inotropic action.7 8 Left bundle branch block does not seem to be a contraindication to treatment, however, and this is confirmed by the experience of others. 47 After three months' treatment with amiodarone we noted a significant fall in serum triiodothyronine and rise in thyroid stimulating hormone, implying a mildly hypothyroid state. None the less, no patient developed clinical signs of hypothyroidism, which accords with the small increase in the concentration of thyroid stimulating hormone. The assay for thyroid stimulating hormone is insensitive at low concentrations, however, and this result should be interpreted with caution. We found no clinical or biochemical evidence of hyperthyroidism in this study. The mechanism by which amiodarone blocks the conversion of thyroxine to triiodothyronine has been reviewed elsewhere. 48 Tests of pulmonary function were unaffected by amiodarone, perhaps because the duration of treatment was short. 49 One patient developed symptoms suggestive of peripheral neuropathy on 200 mg/day. After the study he continued to take amiodarone 100 mg/day with resolution of symptoms and continuing arrhythmia control. These and other side effects of amiodarone have been well reviewed by Harris et al and McKenna et al. 50 51
In conclusion, amiodarone seems to be an effective treatment for arrhythmias in heart failure and does not worsen symptoms or exercise tolerance. Its use in conjunction with captopril appears to be safe. Occasional patients may have worsening of their arrhythmias after amiodarone; this appears early after its introduction and close supervision is recommended to prevent adverse reactions.
